Proteome expression changes upon Halofuginone treatment

ABSTRACT: NHCF-V primary cardiac fibroblasts where treated for 24 hours with either 1) 100nM Halofuginone (TMT labels 126 and 129L) 2) 300nM Halofuginone (TMT labels 127L and 129H) 3) 300 nM Halofuginone + 4 mM L-Pro (TMT labels 127H and 130L) 4) DMSO (TMT labels 128H and 131)

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Primary Cell, Fibroblast

SUBMITTER: Maria Faelth Savitski  

LAB HEAD: Marcus Bantscheff

PROVIDER: PXD005679 | Pride | 2017-05-16

REPOSITORIES: Pride